MDL 74,968, a new acyclonucleotide analog: Activity against human immunodeficiency virus in vitro and in the hu-PBL-SCID.beige mouse model of infection

被引:7
作者
Bridges, CG [1 ]
Taylor, DL [1 ]
Ahmed, PS [1 ]
Brennan, TM [1 ]
Hornsperger, JM [1 ]
Nave, JF [1 ]
Casara, P [1 ]
Tyms, AS [1 ]
机构
[1] MARION MERRELL DOW RES INST,F-67080 STRASBOURG,FRANCE
关键词
D O I
10.1128/AAC.40.5.1072
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The novel acyclonucleotide derivative of guanine, 9-[2-methylidene-3-(phosphonomethoxy)propyl]guanine guanine (MDL 74,968), had antiviral activity comparable to those of 9-(2-phosphonomethoxyethyl) adenine (PMEA) and 2',3'-dideoxyinosine against laboratory strains of both human immunodeficiency virus (HIV) types 1 and 2 cultured in MT-4 cells and several clinical HIV isolates cultured in human peripheral blood mononuclear cells (PBMCs). MDL 74,968 was at least fourfold less toxic than PMEA to MT-4 cells or PBMCs, thereby producing a more favorable in vitro selectivity index for the former compound. Studies of acute toxicity in CD-1 mice showed that MDL 74,968 was not toxic at doses of 1,600 mg/kg of body weight via the intraperitoneal route or at doses of 500 mg/kg via the intravenous route. Furthermore, no adverse effects of MDL 74,968 were apparent when mice were treated at doses of 200 mg/kg twice daily for 5 days. Treatment by continuous subcutaneous infusion of MDL 74,968 or PMEA at the daily dose of 20 mg/kg in the hu-PBL-SCID.beige murine model of HIV infection significantly reduced the severity of infection compared with that in placebo-treated controls. Quantitation of virus recovery by endpoint titration of spleen cells in coculture with mitogen-activated PBMCs demonstrated that MDL 74,968 as well as PMEA significantly reduced the amount of virus (P < 0.02). Moreover, by using DNA extracted from spleens, the mean HIV:HLA PCR product ratio, which takes into account individual variation in immune system reconstitution, were 0.50 and 0.40 for MDL 74,968 and PMEA treatments, respectively, whereas animals receiving the placebo control had significantly higher levels of HIV proviral DNA (mean 0.78; P < 0.02). Taken together, these promising findings suggest that an orally bioavailable prodrug of MDL 74,968 should be developed for the treatment of HIV infection.
引用
收藏
页码:1072 / 1077
页数:6
相关论文
共 37 条
[1]   EFFICACY OF AZT THERAPY IN REDUCING P24 ANTIGEN BURDEN IN A MODIFIED SCID MOUSE MODEL OF HIV-INFECTION [J].
ALDER, J ;
HUI, YH ;
CLEMENT, J .
ANTIVIRAL RESEARCH, 1995, 27 (1-2) :85-97
[2]   HIV INDUCES THYMUS DEPLETION INVIVO [J].
BONYHADI, ML ;
RABIN, L ;
SALIMI, S ;
BROWN, DA ;
KOSEK, J ;
MCCUNE, JM ;
KANESHIMA, H .
NATURE, 1993, 363 (6431) :728-732
[3]   THE INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN-VITRO BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR MKC-442, ALONE AND IN COMBINATION WITH OTHER ANTI-HIV COMPOUNDS [J].
BRENNAN, TM ;
TAYLOR, DL ;
BRIDGES, CG ;
LEYDA, JP ;
TYMS, AS .
ANTIVIRAL RESEARCH, 1995, 26 (02) :173-187
[4]   SYNTHESIS AND ANTIVIRAL ACTIVITY OF RIGID ACYCLONUCLEOTIDE ANALOGS [J].
CASARA, PJ ;
ALTENBURGER, JM ;
TAYLOR, DL ;
TYMS, AS ;
KENNY, M ;
NAVE, JF .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (12) :1275-1280
[5]   ORAL, SUBCUTANEOUS, AND INTRAMUSCULAR BIOAVAILABILITIES OF THE ANTIVIRAL NUCLEOTIDE ANALOG 9-(2-PHOSPHONYLMETHOXYETHYL) ADENINE IN CYNOMOLGUS MONKEYS [J].
CUNDY, KC ;
SHAW, JP ;
LEE, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :365-368
[6]   BROAD-SPECTRUM ANTI-DNA VIRUS AND ANTIRETROVIRUS ACTIVITY OF PHOSPHONYLMETHOXYALKYLPURINES AND PHOSPHONYLMETHOXYALKYLPYRIMIDINES [J].
DECLERCQ, E .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (05) :963-972
[7]  
DECLERCQ E, 1987, ANTIVIR RES, V8, P261
[8]   SUPPRESSION OF FELINE IMMUNODEFICIENCY VIRUS-INFECTION INVIVO BY 9-(2-PHOSPHONOMETHOXYETHYL)ADENINE [J].
EGBERINK, H ;
BORST, M ;
NIPHUIS, H ;
BALZARINI, J ;
NEU, H ;
SCHELLEKENS, H ;
DECLERCQ, E ;
HORZINEK, M ;
KOOLEN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (08) :3087-3091
[9]   9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE IN THE TREATMENT OF MURINE ACQUIRED IMMUNODEFICIENCY DISEASE AND OPPORTUNISTIC HERPES-SIMPLEX VIRUS-INFECTIONS [J].
GANGEMI, JD ;
COZENS, RM ;
DECLERCQ, E ;
BALZARINI, J ;
HOCHKEPPEL, HK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (11) :1864-1868
[10]   PREEXPOSURE AND POSTEXPOSURE PROTECTION AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION MEDIATED BY A MONOCLONAL-ANTIBODY [J].
GAUDUIN, MC ;
SAFRIT, JT ;
WEIR, R ;
FUNG, MSC ;
KOUP, RA .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (05) :1203-1209